Molecular Targets - Prostate Cancer

我们正在使用一种新的策略来确定治疗和预防常见癌症的分子靶点，最初的重点是前列腺癌。该策略利用数据挖掘基因组信息，通过NCI癌症基因组解剖项目（CGAP）生成并提供给公众，并将这些信息与湿实验室方法相结合。具体来说，我们查询了CGAP数据库，使用通过CGAP倡议提供的工具，并与LPG联合开发，以确定在前列腺癌中表达而在其他正常基本组织中不表达的基因。该信息与使用Affymetrix HGU95A-E表达阵列分析基因表达产生的数据相结合。我们预计，初步投资用于确定在基本器官中未表达的靶标，将有助于开发有效的、无毒的癌症治疗药物。此外，这种方法应该促进治疗剂的更快发展，因为它不依赖于对所涉及的细胞机制和途径的完全理解。除了确定药物开发感兴趣的靶标之外，很明显，这些靶标也可以用于药物输送，作为疾病的早期分子标记，或作为药物输送和药物有效性的替代标记。因此，这种一般的、系统的策略应该有助于确定预防和检测许多常见癌症的目标。

We are using a novel strategy to identify molecular targets for the therapy and prevention of common cancers, with an initial focus on prostate cancer. The strategy capitalizes on data mining genomic information, generated and made available to the public through the NCI Cancer Genome Anatomy Project (CGAP), and combines this information with a wet-lab approach. Specifically, we have queried the CGAP database, using tools provided through the CGAP initiative and developed in association with the LPG, to determine genes that are expressed in prostate cancer and not expressed in other normal essential tissues. This information is combined with data generated through the analysis of gene expression using the Affymetrix HGU95A-E expression arrays. We anticipate that the initial investment spent delimiting targets not expressed in essential organs will facilitate the development of effective, non-toxic agents for cancer treatment. In addition, this approach should facilitate the more rapid development of therapeutic agents, because it does not rely on a complete understanding of the cellular machinery and pathways involved. In addition to identifying targets of interest for drug development, it is clear that such targets could also be exploited for drug delivery, as early molecular markers of disease, or as surrogate markers for drug delivery and drug effectiveness. Thus, this general, systematic strategy should be useful in the identification of targets for the prevention and detection of many common cancers.